Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Sana Biotechnology Inc — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.52, while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Roundhill Russell 2000 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| RDTE | SANA | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $34.72 | $5.92 |
52-Week Low | $26.40 | $2.68 |
Market Cap | — | $879.40M |
Enterprise Value | — | $853.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDTE stock trades at $28.57, down 0.38% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company has announced multiple small dividends for 2026, but key valuation and profitability ratios are unavailable. Recent news highlights concerns about the fund's strategy and capital erosion risks.
The outlook is cautious due to structural risks in the covered call strategy capping upside and exposing downside, as noted by Seeking Alpha. Investment opportunity hinges on income from dividends, but risks of NAV deterioration and negative media sentiment present significant headwinds for shareholders.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
